VALARTH See Global Health in the appOpen in app
MEDANTA · NSE · Hospital

Global Health Ltd

What the numbers mean, from its filings and the exchange. Data as of 13 Oct 2026.
Small Cap · AMFI list Jan-Jun 2026 · Vendor sector: Healthcare
fair low confidence No valuation within 120 days; P/E 63.4 vs peers 56.6 (8th of 12); P/B 6.4 vs peers 9.2 (2nd of 11).
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Global Health's share price today?

Global Health last traded at ₹1,281.20 on the NSE, as of 13 Oct 2026, 11:45 am IST, down 2.1% on the day, down 3.9% over a year. Its 52-week range is ₹956 to ₹1,544. The live price is in the app.

₹1,281.20 −2.1% today
−3.9% over 1 year · NSE, as of 13 Oct 2026, 11:45 am IST
47 month-end closes, 30 Nov 2022 to 30 Sep 2026, adjusted for splits and bonuses
52-week range55% of the way up
Low ₹956High ₹1,544

What is Global Health's market cap?

Global Health's market capitalisation is about ₹35,206 crore: what it would cost to buy every share at today's price. That makes it the 16th largest small cap company we cover.

₹35,206 Cr Small Cap16th largest small cap company
Small Cap means the companies ranked 251 and below by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: MEDANTA
ISIN
INE474Q01031
Cap bucket
Small Cap, 16th largest by market cap
Industry (NSE)
Healthcare › Healthcare Services › Hospital
Listed since
2022
Futures and options
Not traded

Is Global Health overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 63.4 vs peers 56.6 (8th of 12); P/B 6.4 vs peers 9.2 (2nd of 11).

Valuation

Latest price and trailing 12 months
P/E 63.42
vs peers 56.6 · 8th of 12
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 6.44
vs peers 9.2 · 2nd of 11
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹35,206 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 0.1%
vs peers 0.3% · 7th of 7
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) Not available
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 3.46
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Global Health a quality business?

Quality score 65.2, 2nd of 12 in its peer set; CLEAN on 28 of 30 flags judged.

Quality and risk

Data as of 13 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 65.2
vs peers 38.3 · 2nd of 12
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level CLEAN
28 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 13.2%
vs peers 8.3% · 4th of 12
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 15.9%
vs peers 10.3% · 4th of 12
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 11.6%
vs peers 8.9% · 5th of 12
Profit after everything, as a share of revenue. Learn more →
EPS ₹20.62
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Global Health made money for shareholders?

Not over these periods: −3.9% over one year.

Shareholder returns

1-year return −3.9%
Price only
What the share price did over the last 12 months. Learn more →
5-year return Not available
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer Not available
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
+0.7%
1M
−7.7%
3M
−1.4%
6M
+23.4%
1Y
−3.9%
3Y
+20.3%
5Y
—
— not available

Does Global Health pay a dividend?

Yes. Global Health's dividend yield is 0.05% at the latest price; the last payout was ₹0.50 a share, ex-dividend 14 Aug 2026.

Dividends

Per share, by ex-dividend date
Dividend yield0.05%
The past 12 months' dividends as a share of today's price.
14 Aug 2026 · Final₹0.50
22 Aug 2025 · Final₹0.50
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Global Health growing?

Revenue 3 years 18.0% a year; profit 3 years 19.5% a year; revenue 5 years 16.8% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 18.0% a year
vs peers 19.8% · 7th of 12
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 19.5% a year
vs peers 9.9% · 5th of 12
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 16.8% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 23.2% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 18.3% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 77.8% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history -0.7%
vs peers -1.1% · 5th of 9
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Global Health do last quarter?

Global Health reported revenue of ₹1,304 Cr, up 19.4% on a year earlier and a net profit of ₹157 Cr, up 15.1% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹1,304 Cr
+19.4% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹157 Cr
+15.1% on a year earlier
What was left for shareholders after every cost and tax.

How does Global Health compare with its peers?

Compared with 11 Hospital; 8th of 12 on P/E; 2nd of 12 on quality score.

Compared with 11 Hospital

11 companies

Global Health against its peers

Largest 10 of 11 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Global Health Ltd₹35,206 Cr63.46.413.2%15.9%−3.9%
Apollo Hospitals Enterprise Ltd₹1.1 L Cr55.210.716.0%17.5%+1.4%
Manipal Health Enterprises Ltd₹89,321 Cr93.8—6.9%8.4%+1.8%
Max Healthcare Institute Ltd₹84,284 Cr59.010.58.3%10.3%−24.3%
Aster DM Quality Care Ltd₹59,221 Cr113.28.89.6%10.9%−3.0%
Fortis Healthcare Ltd₹57,169 Cr56.66.52.1%4.0%−30.9%
Narayana Hrudayalaya Ltd₹34,582 Cr42.812.621.0%18.4%−3.8%
Krishna Institute of Medical Sciences Ltd₹29,577 Cr138.310.211.3%12.6%−1.3%
Dr Agarwals Health Care Ltd₹15,065 Cr101.96.51.9%5.0%−8.5%
Rainbow Childrens Medicare Ltd₹12,483 Cr44.57.015.7%17.3%−7.7%
Park Medi World Ltd₹10,995 Cr37.59.57.5%10.0%+72.0%
Peer median—56.69.28.3%10.3%−1.2%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Global Health?

Global Health is held by promoters 33.0%, foreign institutions 9.5%, domestic institutions 16.9%.

Shareholding pattern

Latest filing, percent of shares
Promoters33.0%
The founders and controlling group.
Foreign institutions9.5%
Overseas funds investing through the FPI route.
Domestic institutions16.9%
Indian insurers, banks, pension and mutual funds together.
Mutual funds16.0%
Indian mutual fund schemes; part of domestic institutions.
Retail and others3.7%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Global Health?

16 analysts cover Global Health, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

16 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Global Health do and what is it sensitive to?

Global Health Limited (Medanta) operates hospitals and related healthcare services, with consolidated revenue from in-patient and out-patient care, pharmacy products and laboratory services. Sensitive to: foreign exchange rates.

Business-model card

FY2025 · 36 verified
4Revenue
3Channels
2Regulators
3Reg. dependencies
3Sensitivities
4Costs
5Geographies

Global Health Limited (Medanta) operates hospitals and related healthcare services, with consolidated revenue from in-patient and out-patient care, pharmacy products and laboratory services. It earns by billing patients and payors, including cash, TPA, government schemes and PSU/corporate payors.

Revenue engine

4 verified
Income from healthcare services (in-patient and out-patient)
Consolidated revenue line split into in-patient and out-patient income; in-patient is the larger of the two in the disaggregation table.
Sale of pharmacy products to out-patients
Revenue recognised when control of the products passes to the customer; sold to out-patients.
Income from laboratory services
Separate consolidated revenue line for laboratory services.
1 more statement
Income from sponsorship and training
Other operating revenue line, recognised in the period in which the services are rendered under agreed terms.

Customers & channels

3 verified
Patients
Patients are the direct service recipients; the company engages them on treatment follow-ups, health awareness and feedback.
CGHS/ ECHS/ Indian Railways payor category
Government scheme payor category shown in the revenue mix by payor; its share of revenue is not stated in the excerpt.
Credit terms with customers
Interpretation: sales are made on nil or 0-90 day credit, so receivables from payors carry collection exposure, which the company tracks through ageing analysis.

Regulators

2 verified
Income-tax authority (Commissioner of Income-tax (Appeals))
Tax disputes on disallowances are pending before this appellate authority; the amounts are contingent liabilities, not booked debts.
Bio-medical waste regulators
Biomedical waste handling is governed by Bio-Medical Waste Rules; the company files annual reports with regulatory authorities to show compliance.

Regulatory dependencies

3 verified
Export promotion schemes (Service exports from India Scheme; Export promotion capital goods scheme)
Benefits on foreign exchange earned under these government schemes are released to other operating revenue once the right to receive them is established; a change to the schemes would move that income.
Income-tax disallowances under appeal
Interpretation: an adverse outcome on these disallowances would convert contingent tax liabilities into cash outflows; timing is not estimable per the note.
Medical and employee-related legal cases
Contingent liabilities are created for these cases except where outflow is remote; outcomes would change liabilities.

Sensitivities

3 verified
Foreign exchange rates
Direction: the company has not hedged FX receivables and payables, so a rise in USD or EUR against INR raises INR cost of foreign-currency deferred payment liabilities and capital creditors, and a fall lowers it.
Interest rates on variable-rate borrowings
Direction: higher rates raise interest expense on variable-rate borrowings, which reduces profit and other equity; lower rates do the reverse.
Average revenue per occupied bed (ARPOB)
Revenue per occupied bed rises with in-patient volumes and ARPOB increases; this is the industry revenue driver the company's pricing and occupancy feed into.

Cost inputs

4 verified
Medical drugs and consumables for in-patient services
Largest stated materials cost line; purchases feed the cost of materials consumed, with closing stock deducted.
Salaries, wages and bonus
Employee benefits expense line; the largest people cost in the statement.
Facility management expenses
Operating expense line in other expenses.
1 more statement
Consumables booked within lease expense
Interpretation: purchases of consumables are presented as lease expense under the Ind AS 116 practical expedient, so lease expense includes consumable costs.

Geographies

5 verified
Five states network
Presence across five states; the company says this spread keeps patient flow steady, including from neighbouring states.
Bed capacity across five states
Network of about 3,000 beds across five states as stated in the annual report.
Bed capacity at March 31, 2025
Total bed capacity across facilities at year end.
2 more statements
Northeast expansion (Assam and neighbouring regions)
A planned expansion aimed at serving people in Assam and neighbouring regions.
Foreign currency inflow
Interpretation: foreign-currency receipts are part of the company's business outside India; the excerpt gives the amount but not the source of the inflow.
Each statement is checked word for word against the FY2025 annual report; the passages are in the app.

What changed recently?

Dividend - Re 0.50 Per Share (14 Aug 2026).

Change log

8 entries · newest first
  1. Corporate actionDividend - Re 0.50 Per Share.
  2. Results filedQ1 FY2027 results filed.
  3. Results filedQ4 FY2026 results filed.
  4. Results filedQ3 FY2026 results filed.
  5. Results filedQ2 FY2026 results filed.
  6. Corporate actionDividend - Re 0.50 Per Share.
  7. Results filedQ1 FY2026 results filed.
  8. Results filedQ4 FY2025 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsCLEAN on 28 of 30 flags judged; no red flag; 2 could not be judged.
  • Data gapsPEG (vendor), Business quality, 5-year return, Wealth destroyer: not available yet.
Not applicable to this company · 1
  • Altman ZAltman Z is a manufacturing model; a service business has no inventory or plant turnover for it to read.

What this page rests on

✓9 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓47 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2025 · 36 verified

Questions people ask

What is Global Health's share price today?

Global Health last traded at ₹1,281.20 on the NSE, as of 13 Oct 2026, 11:45 am IST, down 2.1% on the day, down 3.9% over a year. Its 52-week range is ₹956 to ₹1,544. The live price is in the app.

What is Global Health's market cap?

Global Health's market capitalisation is about ₹35,206 crore: what it would cost to buy every share at today's price. That makes it the 16th largest small cap company we cover.

Is Global Health Ltd a large cap, mid cap or small cap?

Global Health Ltd (MEDANTA) is a small cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Global Health Ltd's P/E ratio?

63.42, vs peers 56.6 · 8th of 12. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Global Health Ltd overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 63.4 vs peers 56.6 (8th of 12); P/B 6.4 vs peers 9.2 (2nd of 11).

How does Global Health Ltd make money?

Global Health Limited (Medanta) operates hospitals and related healthcare services, with consolidated revenue from in-patient and out-patient care, pharmacy products and laboratory services. It earns by billing patients and payors, including cash, TPA, government schemes and PSU/corporate payors.

Who are Global Health Ltd's peers?

Compared with 11 Hospital: Apollo Hospitals Enterprise Ltd, Manipal Health Enterprises Ltd, Max Healthcare Institute Ltd, Aster DM Quality Care Ltd, Fortis Healthcare Ltd and 6 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Global Health do last quarter?

Global Health reported revenue of ₹1,304 Cr, up 19.4% on a year earlier and a net profit of ₹157 Cr, up 15.1% in the Jun 2026 quarter.

Who owns Global Health?

Global Health is held by promoters 33.0%, foreign institutions 9.5%, domestic institutions 16.9%.

Does Global Health pay a dividend?

Yes. Global Health's dividend yield is 0.05% at the latest price; the last payout was ₹0.50 a share, ex-dividend 14 Aug 2026.

What do analysts say about Global Health?

16 analysts cover Global Health, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

More small cap companies

HFCL LtdHFCL · ₹40,634 CrPTC Industries LtdPTCIL · ₹38,553 CrK P R Mill LtdKPRMILL · ₹36,936 CrEmcure Pharmaceuticals LtdEMCURE · ₹35,427 CrAnand Rathi Wealth LtdANANDRATHI · ₹34,653 CrNuvama Wealth Management LtdNUVAMA · ₹34,482 CrHexaware Technologies LtdHEXT · ₹33,597 CrExide Industries LtdEXIDEIND · ₹33,503 Cr
All companies, by market cap →

Everything on Global Health, and 6,621 other companies, with 212 filters and the full peer tables

See Global Health in the app →See pricing